Global RNA Targeting Small Molecule Drug Discovery Market Size study & Forecast, by Indication (Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Other), by End User (Pharmaceutical and Biopharmaceutical Companies, Academic and Resea

Global RNA Targeting Small Molecule Drug Discovery Market Size study & Forecast, by Indication (Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Other), by End User (Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Other) and Regional Analysis, 2023-2030

Global RNA Targeting Small Molecule Drug Discovery Market is valued at approximately USD 1.1 billion in 2022 and is anticipated to grow with a compounded annual growth rate of more than 20.9% over the forecast period 2023-2030. RNA targeting small molecules drug discovery refers to the process of identifying and developing small molecule drugs that specifically target and modulate the activity of RNA molecules within cells. RNA, or ribonucleic acid, plays a crucial role in various cellular processes, including gene expression and regulation. A small molecule is an organic compound with a relatively low, molecular weight that can interact with biological targets such as proteins or nucleic acids. Thus, increasing research and development (R&D) investment and Advancement in RNA Biology are anticipated to elevate the growth of the Global RNA Targeting Small Molecule Drug Discovery Market.

According to the International Agency for Research on Cancer (IARC) in 2018, the global incidence of cancer was approximately 17 million new cases and resulted in 9.5 million cancer related deaths. It is projected that, by 2040, these numbers are anticipated to rise to 27.5 million new cancer cases and 16.3 million cancer related deaths due to population growth and ageing alone. Moreover, the future burden is expected to be even greater as a consequence of escalating risk factors such as smoking, unhealthy diet, physical inactivity, and declining childbirth rates in economically transitioning nations. According to World Bank in 2020, Governments typically allocated just over 2% of their total health budgets to mental health expenses on average. Additionally, many low-income countries reported having fewer than one mental health worker for one lakh individuals. Recognizing the importance of mental health as a significant component of global health and human capital development, the World Bank is actively supporting initiatives to prioritize and integrate mental health services on a global scale which is driving the demand for the RNA Targeting Small Molecule Drug Discovery Market. However, cost, time and delivery challenges may hamper the growth of the Global RNA Targeting Small Molecule Drug Discovery Market. Moreover, government initiatives & regulatory support and high unmet medical needs emerge as some of the growth opportunities for the market.

The key regions considered for the Global RNA Targeting Small Molecule Drug Discovery Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the dominance of branded products and the region's increasing prevalence of diseases. The CDC expected that in 2020, the United States may have approximately 37.3 million individuals with diabetes. This includes 28.7 million diagnosed cases and 8.5 million undiagnosed cases, as diabetes has a genetic basis. The Asia Pacific region is anticipated to experience substantial growth in the forecast period due to factors such as a growing elderly population, increasing target populations, greater collaboration for biosimilar development, expansion of key players into new geographic areas, and active involvement of government and nonprofit organizations in the market.

Major market player included in this report are:
Accent TherapeuticsInc.
Anima Biotech Inc.
AstraZeenca
Epics Therapeutics
Expansion Therapeutics
F.Hoffmann-La Roche Ltd.
H3 Biomedicine Inc.
PTC Therapeutics Inc.
Ribometrix Inc.
Skyhawk Therapeutics Inc.

Recent Developments in the Market:
In January 2023, biotechnology company Businesswire a Berkshire Hathaway Company introduces an innovative RNA structure platform powered by artificial intelligence to address diseases that are currently difficult to treat. The platform utilizes an AI-driven 3-D RNA structure engine to generate a comprehensive data site of RNA structures. By integrating this dataset with machine learning foundation models and extensive in-house experimental wet-lab biology, the platform revolutionizes the field of RNA drug discovery opening new possibilities for the development of RNA-targeted therapies.

In February 2023, ReviR Therapeutics Inc. partnered with Asieris Pharmaceuticals Co. Ltd. To develop new oncology therapies.

Global RNA Targeting Small Molecule Drug Discovery Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered - Indication, End User, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Indication:
Cancer
Infectious Diseases
Metabolic Diseases
Neurological Diseases
Other

By End User:
Pharmaceuticals & Biopharmaceuticals Companies
Academic & Research Institutes
Other

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned
Accent TherapeuticsInc.
Anima Biotech Inc.
AstraZeenca
Epics Therapeutics
Expansion Therapeutics
F.Hoffmann-La Roche Ltd.
H3 Biomedicine Inc.
PTC Therapeutics Inc.
Ribometrix Inc.
Skyhawk Therapeutics Inc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.